Issue link: https://www.e-digitaleditions.com/i/1373953
60 Pharmaceutical Technology BIOLOGICS AND STERILE DRUG MANUFACTURING EBOOK 2021 P h a r mTe c h . c o m Operations B iologics facilities have expanded and advanced within the past few months in terms of significant investments, construction on new facilities, and acquisitions of new locations. The following are a sampling of these advances. Expansions Catalent has completed its expansion of two new mammalian cell culture suites at its biologics drug substance development and manufacturing facility in Madison, Wis. (1). Each suite features a 2 x 2000-L single-use bioreactor system aimed at processing batches of 2000 or 4000 L for current good manufacturing practice (CGMP) clinical and commercial manufacturing. The first engineering batch in one new suite started in March 2021, with the first CGMP batch expected to be manufactured during May 2021. The second suite is set to begin its first engineering batch in May 2021 and its first CGMP batch in July 2021. The new manufacturing suites add to an existing 2 × 2000-L suite, a 1000-L suite, and a 500-L suite. "This new capacity will allow us to meet growing clinical and commercial demand from both existing and new customers," said Mike Riley, region president, Biologics, North America, Catalent, in a press release. "Catalent's continued investment in technology and capacity will enable us to bring our customers' important and innovative treatments to patients faster." Thermo Fisher Scientific plans to invest more than $600 million into the expansion of its bioprocessing production capabilities through 2022 (2). The investments are expected to double Thermo Fisher's Biologics Facilities Expand and Establish New Locations in 2021 Lauren Lavelle The latest news about biologics facilities includes various expansions, new locations, and acquisitions in the bio/pharmaceutical space. PUTILOV_DENIS - STOCK.ADOBE.COM